Piper B F, Rieger P T, Brophy L, Haeuber D, Hood L E, Lyver A, Sharp E
Oncol Nurs Forum. 1989 Nov-Dec;16(6 Suppl):27-34.
Limited information about fatigue patterns in patients with cancer exists in the biotherapy literature. When fatigue is mentioned, it is usually to state whether or not it was a dose-limiting side effect. No further data are provided on how fatigue was measured; which patterns were noted and when; and which relationships were found between fatigue and demographic characteristics, type of biologic response modifier, route of administration, or cumulative dose. Thus, there is little available in the biotherapy literature to guide nursing practice in managing this side effect. Theory that guides practice, however, often emanates from the personal experiences of the patients and from the clinical observations and intuitive hunches of the nurses and physicians participating in clinical trials. These individuals have been most generous in sharing their insights and unpublished data with the authors. This paper presents a comprehensive view of current knowledge on fatigue to guide present nursing practice with patients receiving biotherapy and to provide direction for future nursing and clinical trial research.
生物治疗文献中关于癌症患者疲劳模式的信息有限。当提及疲劳时，通常只是说明它是否是剂量限制性副作用。没有提供关于疲劳如何测量、记录了哪些模式以及何时记录的，以及在疲劳与人口统计学特征、生物反应调节剂类型、给药途径或累积剂量之间发现了哪些关系的进一步数据。因此，生物治疗文献中几乎没有可用于指导护理实践管理这种副作用的内容。然而，指导实践的理论通常源于患者的个人经历以及参与临床试验的护士和医生的临床观察和直觉。这些人非常慷慨地与作者分享他们的见解和未发表的数据。本文全面介绍了当前关于疲劳的知识，以指导目前对接受生物治疗患者的护理实践，并为未来的护理和临床试验研究提供方向。
